CRIS Current Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishBACKGROUND: The major concern regarding the use of low-dose oral minoxidil (LDOM) in the treatment of hair loss is the potential risk of systemic adverse effects.OBJECTIVE: To describe the safety of LDOM for the treatment of hair loss in a large cohort of patients.METHODS: Retrospective multicenter study of patients treated with LDOM for at least 3 months as a treatment for any type of alopecia.RESULTS: A total of 1404 patients [943 women (67.2%) and 461 men (32.8%)] with a mean age of 43 years (range 8-86) were included. From them, the dose of LDOM was titrated in 1065 patients, allowing the analysis of 2469 different cases. The most frequent adverse effect was hypertrichosis (15.1%) which led to treatment withdrawal in 14 patients (0.5%). Systemic adverse effects included lightheadedness (1.7%), fluid retention (1.3%), tachycardia (0.9%), headache (0.4%), periorbital edema (0.3%) and insomnia (0.2%), leading to drug discontinuation in 29 patients (1.2%). No life-threatening adverse effects were observed.LIMITATIONS: Retrospective design, lack of a control group.CONCLUSION: LDOM has a good safety profile as a treatment for hair loss. Systemic adverse effects were infrequent and only 1.7% of patients stopped the treatment due to adverse effects.
| Titolo: | Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients | |
| Autore/i: | Vano-Galvan, S; Pirmez, R; Hermosa-Gelbard, A; Moreno-Arrones, O M; Saceda-Corralo, D; Rodrigues-Barata, R; Jimenez-Cauhe, J; Koh, W L; Poa, J; Jerjen, R; Trindade de, Carvalho L; John, J; Salas-Callo, C I; Vincenzi, C; Yin, L; Lo-Sicco, K; Waskiel-Burnat, A; Starace, M; Zamorano, J L; Jaén-Olasolo, P; Piraccini, B M; Rudnicka, L; Shapiro, J; Tosti, A; Sinclair, R; Bhoyrul, B | |
| Autore/i Unibo: | ||
| Anno: | 2021 | |
| Rivista: | ||
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.jaad.2021.02.054 | |
| Abstract: | BACKGROUND: The major concern regarding the use of low-dose oral minoxidil (LDOM) in the treatment of hair loss is the potential risk of systemic adverse effects.OBJECTIVE: To describe the safety of LDOM for the treatment of hair loss in a large cohort of patients.METHODS: Retrospective multicenter study of patients treated with LDOM for at least 3 months as a treatment for any type of alopecia.RESULTS: A total of 1404 patients [943 women (67.2%) and 461 men (32.8%)] with a mean age of 43 years (range 8-86) were included. From them, the dose of LDOM was titrated in 1065 patients, allowing the analysis of 2469 different cases. The most frequent adverse effect was hypertrichosis (15.1%) which led to treatment withdrawal in 14 patients (0.5%). Systemic adverse effects included lightheadedness (1.7%), fluid retention (1.3%), tachycardia (0.9%), headache (0.4%), periorbital edema (0.3%) and insomnia (0.2%), leading to drug discontinuation in 29 patients (1.2%). No life-threatening adverse effects were observed.LIMITATIONS: Retrospective design, lack of a control group.CONCLUSION: LDOM has a good safety profile as a treatment for hair loss. Systemic adverse effects were infrequent and only 1.7% of patients stopped the treatment due to adverse effects. | |
| Data stato definitivo: | 2022-02-27T16:38:57Z | |
| Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
Copyright © 2022